Episode 110
On this week’s episode, hosts Josh Schimmer, Sam Fazeli, Brian Skorney, Michal Preminger and Eric Schmidt kick off the show by discussing the recent growth in XBI performance. The group weighs in on IPO dynamics, hypothesizing on the influence of investors and the power of FOMO. They go on to note the success of Viking Therapeutics as they’re moving into Phase 3 for their GLP-1 agonist, and what the future may hold for the weight-loss drug market. Shifting gears, the hosts raise concerns on CHMP issuing a negative opinion of Leqembi for Alzheimer’s disease, signaling a shift in the relation of CHMP and FDA standards. The group also discusses PBM execs facing heat from the House Oversight Committee as well as recent rare disease news including the FDA’s launch of a Rare Disease Innovation Hub. The hosts also highlight the growing success of gene therapy and close the show by discussing one of the top ten rules of engagement for biotech executives. *This episode aired on July 26, 2024.
Available Results
Generated results are saved to the knowledge database for reuse and search.
Extract Knowledge
Pick what you want extracted first. Model, scope, and chapter options appear after a template is selected.